US public health group attacks safety of GSK's asthma drug
By Stephen Foley, The Independent
Published: 07 October 2005
An American consumer campaign group claims GSK manipulated results of a 26,000-patient study of its asthma treatment Serevent, which is known as Advair when in combination with another drug.
GSK's response is also published by The Lancet, and the drug company moved yesterday to limit the damage, saying that the claims were false, and it had acted transparently and in good faith while the 26,000-patient "Smart" trial data was being fully understood.
The Lancet articles (registration required)
Misleading data analyses in salmeterol (SMART) study